Last reviewed · How we verify

zidovudine-lamivudine-nevirapine

University of California, San Diego · FDA-approved active Small molecule Quality 2/100

zidovudine-lamivudine-nevirapine is a Small molecule drug developed by University of California, San Diego. It is currently FDA-approved. Also known as: Retrovir, Epivir, Viramune.

At a glance

Generic namezidovudine-lamivudine-nevirapine
Also known asRetrovir, Epivir, Viramune
SponsorUniversity of California, San Diego
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about zidovudine-lamivudine-nevirapine

What is zidovudine-lamivudine-nevirapine?

zidovudine-lamivudine-nevirapine is a Small molecule drug developed by University of California, San Diego.

Who makes zidovudine-lamivudine-nevirapine?

zidovudine-lamivudine-nevirapine is developed and marketed by University of California, San Diego (see full University of California, San Diego pipeline at /company/university-of-california-san-diego).

Is zidovudine-lamivudine-nevirapine also known as anything else?

zidovudine-lamivudine-nevirapine is also known as Retrovir, Epivir, Viramune.

What development phase is zidovudine-lamivudine-nevirapine in?

zidovudine-lamivudine-nevirapine is FDA-approved (marketed).

Related